Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kylie D Mason

Showing results (1-10 of 25) with videos related to

Pageof 3
Sort By:
Leukemia & Lymphoma|January 31, 2008
Go with the flow for monitoring response in myeloma with minimal residual diseaseKylie D Mason, Surender Juneja
European Journal of Haematology|October 31, 2012
Marked eosinophilia with abnormal basophilic granules in acute graft-versus-host disease post-allogeneic haemopoietic stem cell transplant for acute myeloid leukaemia without CBFB-MYH11 mutationEdward Chew, Kylie D Mason, Surender Juneja
Blood Reviews|September 28, 2005
The immunophenotype of acute myeloid leukemia: is there a relationship with prognosis?Kylie D Mason, Surender K Juneja, Jeff Szer
Proceedings of the National Academy of Sciences of the United States of America|November 14, 2008
In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomasKylie D Mason, Cassandra J Vandenberg, Clare L Scott, et al.
Leukemia & Lymphoma|January 15, 2025
Routine magnetic resonance central nervous system imaging may be avoided in high-risk systemic diffuse large B-cell lymphoma with negative cerebrospinal fluid analysesRory Bennett, Manu Juneja, Mary Ann Anderson, et al.
Leukemia & Lymphoma|June 18, 2020
Open-Label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed/refractory aggressive B-cell non-Hodgkin lymphomaLuke Coyle, Nicholas J Morley, Alessandro Rambaldi, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 11, 2010
BH3 mimetics antagonizing restricted prosurvival Bcl-2 proteins represent another class of selective immune modulatory drugsEmma M Carrington, Ingela B Vikstrom, Amanda Light, et al.
Diabetologia|October 11, 2014
Autoreactive T cells induce necrosis and not BCL-2-regulated or death receptor-mediated apoptosis or RIPK3-dependent necroptosis of transplanted islets in a mouse model of type 1 diabetesYuxing Zhao, Nicholas A Scott, Stacey Fynch, et al.
European Journal of Cancer Care|February 11, 2021
Cancer during pregnancy: A qualitative study of healthcare experiences of Australian womenLesley Stafford, Michelle Sinclair, Katrin Gerber, et al.
Blood|February 23, 2013
Low adhesion receptor levels on circulating platelets in patients with lymphoproliferative diseases before receiving Navitoclax (ABT-263)Jianlin Qiao, Simone M Schoenwaelder, Kylie D Mason, et al.
Pageof 3

Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
Leukemia & Lymphoma|January 31, 2008
Go with the flow for monitoring response in myeloma with minimal residual diseaseKylie D Mason, Surender Juneja
European Journal of Haematology|October 31, 2012
Marked eosinophilia with abnormal basophilic granules in acute graft-versus-host disease post-allogeneic haemopoietic stem cell transplant for acute myeloid leukaemia without CBFB-MYH11 mutationEdward Chew, Kylie D Mason, Surender Juneja
Blood Reviews|September 28, 2005
The immunophenotype of acute myeloid leukemia: is there a relationship with prognosis?Kylie D Mason, Surender K Juneja, Jeff Szer
Proceedings of the National Academy of Sciences of the United States of America|November 14, 2008
In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomasKylie D Mason, Cassandra J Vandenberg, Clare L Scott, et al.
Leukemia & Lymphoma|January 15, 2025
Routine magnetic resonance central nervous system imaging may be avoided in high-risk systemic diffuse large B-cell lymphoma with negative cerebrospinal fluid analysesRory Bennett, Manu Juneja, Mary Ann Anderson, et al.
Leukemia & Lymphoma|June 18, 2020
Open-Label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed/refractory aggressive B-cell non-Hodgkin lymphomaLuke Coyle, Nicholas J Morley, Alessandro Rambaldi, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 11, 2010
BH3 mimetics antagonizing restricted prosurvival Bcl-2 proteins represent another class of selective immune modulatory drugsEmma M Carrington, Ingela B Vikstrom, Amanda Light, et al.
Diabetologia|October 11, 2014
Autoreactive T cells induce necrosis and not BCL-2-regulated or death receptor-mediated apoptosis or RIPK3-dependent necroptosis of transplanted islets in a mouse model of type 1 diabetesYuxing Zhao, Nicholas A Scott, Stacey Fynch, et al.
European Journal of Cancer Care|February 11, 2021
Cancer during pregnancy: A qualitative study of healthcare experiences of Australian womenLesley Stafford, Michelle Sinclair, Katrin Gerber, et al.
Blood|February 23, 2013
Low adhesion receptor levels on circulating platelets in patients with lymphoproliferative diseases before receiving Navitoclax (ABT-263)Jianlin Qiao, Simone M Schoenwaelder, Kylie D Mason, et al.
Pageof 3